MAPK regulation of maternal and zygotic Notch transcript stability in early development

Foster C. Gonsalves and David A. Weisblat*

Department of Molecular and Cell Biology, 385 LSA, University of California, Berkeley, CA 94720-3200

Communicated by John C. Gerhart, University of California, Berkeley, CA, November 13, 2006 (received for review March 16, 2006)

Spatiotemporal modulation of the evolutionarily conserved, intercellular Notch signaling pathway is important in the development of many animals. Examples include the regulation of neuralepidermal fate decisions in neurogenic ectoderm of Drosophila and somitogenesis in vertebrate presomitic mesoderm. In both these and most other cases, it appears that Notch-class transmembrane receptors are ubiquitously expressed. Modulation of the pathway is achieved primarily by the localized expression of the activating ligand or by alteration of receptor specificity through a glycosyl transferase. In contrast, we present this report of an instance where the abundance of the Notch-class mRNA itself is dynamically regulated. Taking advantage of the long cell cycle of the two-cellstage embryo of the leech Helobdella robusta, we show that this regulation is achieved at the levels of both transcript stability and transcription. Moreover, MAPK signaling plays a significant role in regulating accumulation of the transcript by virtue of its effect on Hro-notch mRNA stability. Intracellular injection of heterologous reporter mRNAs shows that the Hro-notch 3' UTR, containing seven AU-rich elements, is key to regulating transcript stability. Thus, we show that regulation of the Notch pathway can occur at a previously underappreciated level, namely that of transcript stability. Given that AU-rich elements occur in the 3' UTR of Notch-class genes in Drosophila, human, and Caenorhabditis elegans, regulation of Notch signaling by modulation of mRNA levels may be operating in other animals as well.

Helobdella | leech | mRNA turnover | 3' UTR

N otch signaling functions in a variety of developmental contexts in different embryonic and tissue systems (1). The main framework of the pathway is evolutionarily conserved; thus, its many roles reflect cooption of an ancestral signaling pathway. Notch signaling regulates diverse functions such as neurogenesis and pattern formation in embryonic development. Regulation of the Notch signaling pathway has been studied extensively, with the conclusion that regulation of Notch itself occurs mainly at the translational or posttranslational levels (2, 3). For example, in the eight-cell Caenorhabditis elegans embryo the *notch* homolog *glp-1* is expressed uniformly in all of the cells; restriction of signaling is achieved by regulated translation of the glp-1 mRNA in a cell-specific manner (3). Posttranslation regulation of Notch is achieved by processes such as glycosylation (4) or by regulated degradation of the signal-transducing Notch intracellular domain (5). Little is known about the regulation of notch mRNA itself.

Here, we report that both transcription and mRNA stability are involved in generating a dynamic pattern of *Hro-notch* mRNA expression in the two-cell embryo of the leech *Helobdella robusta*. The cellular simplicity and the long cell cycle of the two-cell leech embryo allowed us to address the temporal dynamics of *Hro-notch* mRNA stability in detail. Our demonstration of 3' UTR-regulated, oscillating expression of *Notch*class transcript levels represents a previously uncharacterized mode of regulation of this ancient and ubiquitous signaling pathway. Furthermore, the presence of pentameric AU-rich elements (AREs) in the 3' UTR of *Hro-notch* as well as those from other species, and the correlation of *Hro-notch* expression with p38MAPK phosphorylation suggest that this mechanism may also be operative in other organisms. Such 3' UTRmediated transcript stability has been reported for mRNAs encoding cytokines (6), but this work demonstrates that this mechanism can also operate for the Notch receptor. Previous studies have demonstrated a role for the ERK pathway in regulating Notch expression and signaling in *Drosophila* and *C. elegans*, respectively (7, 8). The role of the p38MAPK pathway in regulation of Notch transcript levels, introduces another mode of cross-talk between two distinct signal-transduction pathways.

Results and Discussion

Helobdella development is characterized by determinate lineages, beginning with an unequal first cleavage. Prolonged cell cycles and the ability to stage embryos precisely (relative to polar body formation or the initiation of first cleavage) permit us to observe developmental events with good temporal resolution relative to the cell cycles and cell divisions during cleavage. The examination of such carefully timed embryos by in situ hybridization under identical reaction conditions reveals a dynamic pattern of Hro-notch mRNA levels during the two-cell stage. *Hro-notch* is present as a maternal transcript (Fig. 1A), and *in situ* hybridization shows Hro-notch at uniform, basal levels in the zygote and in both blastomeres (AB and CD) at time points immediately after first cleavage (265-280 min after zygote deposition (AZD) (Fig. 1B). Beginning \approx 15 min after cytokinesis, however, the in situ signal starts to fluctuate in a reproducible manner, being stronger first in CD (in 78%; n = 14 of 18 stained embryos at 280–295 min AZD; Fig. 1C), and then in AB (in 84%; n = 67 of 80 stained embryos at 305-325 min AZD; Fig. 1D), and finally in CD again (in 58%; n = 18 of 31 stained embryos at 340-355 min AZD; Fig. 1E). We call these periods of biased expression the CD-1, the AB, and the CD-2 phases, respectively. Embryos fixed at most time points show a mix of staining patterns that we attribute to errors in timing, developmental noise, and the transition from one phase to another [Fig. 1G; and see supporting information (SI) Fig. 6). After the CD-2 phase, none of the embryos processed for in situ hybridization showed staining in either of the blastomeres (Fig. 1F) until the second cleavage. Hro-notch expression continues in various cells throughout cleavage (9), but to analyze mechanisms regulating this dynamic expression pattern, we chose to take advantage of the cellular simplicity of the two-cell leech embryo, in which we have documented a similarly dynamic pattern of WNT protein expression and signaling (10).

We hypothesized that this dynamic pattern of *Hro-notch* mRNA expression reflects a well regulated and cell-specific

Author contributions: F.C.G. designed research; F.C.G. performed research; F.C.G. and D.A.W. analyzed data; and F.C.G. and D.A.W. wrote the paper.

The authors declare no conflict of interest.

Abbreviations: ARE, AU-rich element; AZD, after zygote deposition; PAE, polyadenylation element; sqRT-PCR, semiquantitative RT-PCR.

^{*}To whom correspondence should be addressed. E-mail: weisblat@berkeley.edu.

This article contains supporting information online at www.pnas.org/cgi/content/full/ 0609851104/DC1.

^{© 2007} by The National Academy of Sciences of the USA



Fig. 1. Dynamic, expression of *Hro-notch* mRNA in the two-cell *Helobdella* embryo (265–370 min AZD; AB is up in this and all subsequent figures). (*A–F*) Zygote and two-cell-stage embryos processed by *in situ* hybridization for *Hro-notch* under identical conditions; those shown in *B–E* are from a single experiment. (*G*) Numerical analysis of two-cell embryos stained for *Hro-notch* shows that predominant patterns follow the progression summarized in the color-coded time line in *A–F* and in subsequent figures. Data presented are from a total of 178 two-cell embryos. (*H*) sqRT-PCR from control embryos (blue) reveals a steady increase in *Hro-notch* mRNA luring the two-cell stage. This increase is abolished by treatment with actinomycin-D (purple) or U0126 (orange). Actinomycin-D has no effect on mRNA levels until after 300 min AZD (*P* > 0.05). U0126 treatment, however, induces a significant decline in the amount of *Hro-notch* mRNA starting from early stage 2 (*P* < 0.005). sqRT-PCR was done on groups of five embryos in each time window. Data shown are a compilation of a total of five experiments; at each time point, error bars represent standard error (SEM). (Scale bar: 100 μ m.)

combination of differential mRNA stability and/or zygotic transcription. Comparing embryos fixed during the different phases and processed in parallel for *in situ* hybridization revealed that staining intensity of blastomere CD during the CD-1 phase is roughly comparable to the basal levels seen in the zygote and in both blastomeres immediately after first cleavage. This finding suggested that the CD-1 phase of cell-specific *Hro-notch* expression resulted from the loss of *Hro-notch* mRNA in cell AB. In contrast, staining in the AB and CD blastomeres during AB-1 and CD-2 phases, respectively, is more intense than the earlier staining. This observation, coupled with the reappearance of *in situ* signal after it has been lost in both AB and CD, suggests that the dynamic *in situ* pattern reflects zygotic transcription of *Hro-notch*, at least during the mid and late two-cell stage (305 min AZD onwards).

To test whether zygotic transcription is associated with the observed *in situ* hybridization pattern, we performed semiquantitative RT-PCR (sqRT-PCR) on precisely timed two-cell embryos, cultured either in medium containing a transcription inhibitor (500 μ g/ml of actinomycin-D in Htr medium containing 0.1% DMSO) or an equivalent concentration of DMSO alone. The DMSO-treated control embryos show a significant increase

in *Hro-notch* mRNA during the AB and CD-2 phases of the two-cell stage relative to earlier time points, and actinomycin-D treatment abolishes this increase (Fig. 1*H*). Similar results were obtained from embryos injected with another transcription inhibitor (α -amanitin), and inhibitor-treated embryos show a decrease in the *in situ* staining associated with the AB and CD-2 phases (data not shown). These data indicate that the AB and CD-2 phases of *Hro-notch* expression are associated with accumulation of zygotic transcripts in AB and CD blastomeres, respectively, and that zygotic transcription contributes little to the CD-1 phase. Thus ,the CD-1 phase is a reflection of selective stabilization of maternal *Hro-notch* mRNA in blastomere CD relative to that in blastomere AB.

Differential mRNA stability is affected by intracellular factors that interact with structural elements commonly located within the 3' UTR of specific mRNAs (11). The p38MAPK pathway has been implicated in regulating the stability of mRNAs bearing the pentameric AREs, AUUUA (6). It has been proposed that p38MAPK influences the interaction between AREs and cytoplasmic factors by phosphorylating such transacting factors (12–15); specifically, activated p38MAPK stabilizes ARE-bearing mRNAs by in-

hibiting ARE-mediated degradation (16). Thus AREs can exert either a stabilizing or destabilizing effect on the mRNA molecule (17, 18), depending on the p38MAPK activity within the cell. The strength of the effect varies with the number and configuration of AREs in the transcript (19). Examination of the 3' UTR of Hro-notch (9) revealed seven pentameric AREs 5' to the polyadenylation element. Two of these AREs overlap and, with adjacent sequences, form two overlapping nonameric AREs, one with the sequence UUAUUUAUU and the other with the sequence UUAUUUAAA (Fig. 4E). This configuration with overlapping nonameric AREs corresponds to a class 2 ARE configuration (20). Class 2 ARE-bearing mRNAs, such as those encoding the cytokine Cox2, are known to destabilize the mRNA. This destabilization is counteracted by p38MAPK activity (21, 22). Thus, Hro-notch mRNA, which also bears class 2 AREs in its 3' UTR, is a strong candidate for p38MAPK-regulated transcript stability.

To determine whether p38MAPK is activated in the two-cell leech embryo, we immunostained embryos with a commercially available antibody against the diphosphorylated form of p38MAPK (p38MAPKpp). Using an HRP-DAB protocol (see *Materials and Methods*) to visualize the immunostaining signal, we observed a dynamic pattern of p38MAPKpp immunoreactivity in the cytoplasm that parallels the three phases of *Hro-notch* mRNA expression and, thus, is consistent with a role for p38MAPKpp in posttranscriptional mRNA regulation (Fig. 2 A–C).

The immunostaining pattern was reproducible and was seen with two different coloration times (Fig. 2 A–C and A'–C'). However, as has been seen in other whole-mount MAPKpp immunostaining experiments (23), the difference in staining intensity between the immunopositive and immunonegative cells was relatively low. To further examine the differential activation of p38MAPK, we also tested for nuclear translocation of p38MAPKpp. For this purpose, we let a few embryos from each reaction undergo longer coloration reactions, so as to allow the visualization of the nucleus through the yolk-rich cytoplasm. Such embryos showed nuclear localization of p38MAPKpp in phase with *Hro-notch* expression and cytoplasmic p38MAPKpp (Fig. 2A'-C'). To unequivocally confirm the presence of nuclearly localized p38MAPKpp, we sectioned these embryos and counterstained the sections with a fluorescent DNA stain (4', 6-diamidino-2-phenylindole; DAPI), which normally causes nuclei to fluoresce brightly. In the nuclei of p38MAPKpp immunopositive cells, however, the fluorescence was quenched by the precipitate used to visualize the antibody (Fig. 2 D-G). The nuclear translocation of p38MAPKpp, as judged by fluorescence quenching, correlated with the pattern of cytoplasmic staining, supporting the conclusion that the temporal dynamics of p38MAPK phosphorylation mirror *Hro-notch* mRNA expression. Is there a causal link underlying the coincident patterns of p38MAPK activation and Hro-notch accumulation in the twocell embryo?

To address this question, we performed sqRT-PCR on embryos cultured in the presence of the MAPKK inhibitor U0126 (50 μ M in medium containing 0.1%DMSO). U0126 is widely used as an inhibitor of the ERK kinase (MKK1/2) but also inhibits MKK3/6, the MAPKK responsible for phosphorylation of p38MAPK (24). U0126 treatment, when initiated anytime before stage 4a (7 h AZD) resulted in specific defects in late cleavage (\approx 33 h AZD) (F.C.G., and Ajna S. Rivera, unpublished work) and reduced p38MAPKpp immunoreactivity as measured by Western blot analysis during stage 7 (50 h AZD; SI Fig. 7, and data not shown, and SI Supporting Text). Correlated with these effects, we found that UO126 treatment reduced the accumulation of Hro-notch mRNA relative to vehicle-treated control embryos as judged by sqRT-PCR (Fig. 1H). In particular, U0126-treated embryos showed a statistically significant decline in the amount of transcript during the CD-1 phase that was not seen with the transcription inhibitor, actinomy-



The time course of p38MAPK activation in the two-cell embryo Fig. 2. coincides with Hro-notch expression. Representative images of embryos fixed and stained for diphosphorylated p38MAPK (p38MAPKpp) by using coloration times of \approx 15 min (A–C) and \approx 30 min (A'–C'). p38MAPKpp is detected in the cytoplasm (A) and nucleus (A' black arrowhead) of blastomere CD from 280–295 min AZD and again from 340–350 min AZD (C and C'), corresponding to the CD-1 and CD-2 phases, respectively. Blastomere AB shows localization of p38MAPKpp in its cytoplasm (B) and nucleus (B') from 305-325 min AZD, corresponding to the AB phase. (D-G) Five-micrometer sections of embryos embedded in JB4 resin (Polysciences, Warrington, PA) and viewed by DIC (D and F) and fluorescence (E and G) confirm nuclear localization of p38MAPKpp in blastomere CD during the CD-1 phase (D and E) and in blastomere AB during the AB phase (F and G). Sections were stained for DNA with DAPI and mounted in Fluormount (BDH, Poole, U.K.). p38MAPKpp-immunopositive nuclei are marked by the DAB precipitate (arrowheads in D and F), which quenches the DAPI fluorescence (white circles in E and G) relative to that in the other nucleus in each embryo (red circles in E and G). Nonnuclear blue specs in both E and G are due to autofluorescence from the yolk platelets. Note that during the CD-1 phase there is very little perinuclear cytoplasm separating the nucleus and the yolk in blastomere AB (D). (Scale bars: A–C, 100 μm; D–G, 30 μm.)

cin-D. This result is consistent with our prediction that the CD-1 phase of *Hro-notch in situ* hybridization is due to selective stabilization of maternally inherited *Hro-notch* transcript in blastomere-CD by p38MAPKpp.

Thus, we conclude that the dynamic *Hro-notch in situ* pattern in the two-cell *Helobdella* embryo results from MAPK-mediated regulation of *Hro-notch* transcript stability and is also due to activation of zygotic transcription by an as yet unknown signal. The effect of U0126 on blocking *Hro-notch* accumulation during the AB and CD-2 phases is consistent with the possibility that MAPK signaling also activates zygotic transcription of *Hronotch*, but our experiments do not distinguish between this possible role for MAPK in transcriptional activation and its demonstrated role in transcript stabilization. Moreover, these results do not rule out possible contributions of MAPK pathways other than p38MAPK in this process. In particular, given the U0126 results, it seemed reasonable to consider that ERK signaling also played a role in activating *Hro-notch* transcription during late stage 2, as has been shown for *Drosophila* (7). However, we were unable to detect phosphorylated ERK by using a monoclonal Ab specific for the phosphorylated protein.

To test the hypothesis that the 3' UTR of Hro-notch is sufficient for the observed expression pattern in the two-cell embryo, we injected zygotes with egfp::N3' UTR-pae, a reporter mRNA containing eGFP coding sequence, the 3' UTR of Hro-notch and an SV40 polyadenylation element (PAE) to prevent degradation of nonpolyadenylated mRNA (25, 26). As a control, we injected mRNA containing eGFP and PAE sequences only (egfp-pae). We chose to analyze the in situ pattern of the exogenous egfp mRNA at 275', 285', 310', and 350' (to represent Pre-CD1, CD-1, AB, and CD-2 phases of Hro-notch, respectively), because these time points showed the most robust and least variable staining of Hro-notch during the respective phases (SI Fig. 6). Using *in situ* hybridization for *egfp* to follow the injected mRNAs after first cleavage, we found that, in embryos injected with egfp-pae, blastomeres AB and CD stain with equal intensities at all time points, and the *in situ* signal showed a gradual decline over time (n = 49) (Fig. 3 A–D). In contrast, the staining pattern in embryos injected with *egfp::N3'* UTR-pae recapitulated the early portion of the dynamic Hronotch pattern (Fig. 3A' and B'). AB and CD stained equally in most of the embryos fixed soon after cleavage. Staining was lost from AB in a significant number ($\approx 30\%$) of embryos by time points corresponding to the CD-1 phase (Fig. 3C') and was lost in both cells in most (\approx 71%) of the embryos by the beginning of CD-2 phase (Fig. 3D'). A significant number of embryos during the CD-1 and AB phases retained staining in both cells; we attribute this to the variability in the amount of mRNA delivered intracellularly, which might be above physiologically relevant concentrations in these embryos. Notwithstanding this observation, we point out that none of the embryos showed detectable staining in blastomere AB after the onset of the CD-1 phase, which reflects the rapid degradation of the mRNA in blastomere AB as compared with that in blastomere CD. This finding suggests that the Hro-notch 3' UTR targets the reporter mRNA molecule for degradation and that egfp::N3' UTR-pae mRNA is selectively stabilized in the cell with activated p38MAPK. Moreover, the disappearance of egfp::N3' UTR-pae reporter mRNA during the CD-2 phase further corroborates the interpretation that the Hro-notch in situ signal during this time is indeed due to the accumulation of zygotic transcript.

As a further test of the hypothesis that p38MAPKpp signaling inhibits ARE-mediated degradation of endogenous Hro-notch mRNA, we injected zygotes with *in vitro*-transcribed *Hro-notch* 3' UTR. We predicted that the synthetic mRNA would compete with endogenous transcripts for binding the postulated p38MAPKpp-activated stabilization factors, thereby destabilizing the endogenous transcripts. As predicted, the in situ signal for endogenous Hro-notch, during the AB and CD-2 phases, was reduced in most embryos injected with the 3' UTR (Fig. 4 C and D) compared with those injected with water (Fig. 4 A and B). Using sqRT-PCR to quantify this result, we measured roughly equivalent reductions of endogenous Hro-notch mRNA (26%) and 32% in the AB and CD-2 phases, respectively) in embryos injected with Hro-notch 3' UTR relative to those injected with water (data not shown). The observed level of transcript reduction reflects the balance between enhanced degradation and ongoing transcription. It should be noted that the sqRT-PCR measurements underestimate the extent of the reduction because they were carried out on pools of five embryos each for which the success of the mRNA injections could not be ascertained. These results suggest that even the later (AB and CD-2)



Fig. 3. Destabilization of reporter mRNA by the Hro-notch 3' UTR. Zygotes, injected with equal concentrations of egpf-pae mRNA (A-D) or egfp::N3' UTR-pae mRNA (A'-D'), were fixed at time points corresponding to the color-coded phases of Hro-notch expression (see Fig. 1) and then processed by in situ hybridization for egfp. egpf-pae mRNA is inherited uniformly by blastomeres AB, and CD and is largely stable in both the cells through the two-cell stage. egfp::N3' UTR-pae mRNA is inherited equally by blastomeres AB and CD at first cleavage (A') but shows more pronounced degradation in blastomere AB during the CD-1 phase (compare B and B'). The eqfp::N3' UTR-pae mRNA is cleared from blastomere AB by the AB phase (C') and is mostly degraded in blastomere CD by the CD-2 phase (D'). (E) Numerical distribution of in situ hybridization patterns for egfp in embryos injected with egfp-pae or egfp-N-3' UTR-pae. Note that none of the embryos injected with egfp::N3' UTR-pae mRNA showed a stronger signal in AB than in CD. All embryos (except A and A') were processed for in situ hybridization simultaneously. Coloration reaction for all embryos was limited to 10 min at room temperature in the dark. (Scale bar: 100 μ m.)

phases of *Hro-notch* accumulation reflect the competing dynamics of mRNA transcription, stabilization, and degradation. It appears that when this dynamic is disrupted by the introduction of exogenous *Hro-notch* 3' UTRs that effectively sequester the available stabilization factors, endogenous *Hro-notch* mRNA is targeted for degradation by virtue of the presence of the AREs in its 3' UTR.

In conclusion, we show that transcript levels of a *Notch*-class gene (*Hro-notch*) oscillate antiphasically in the AB and CD blastomeres of the two-cell embryo in the leech *H. robusta*, i.e., high transcript levels in AB are associated with low levels in CD and vice versa (Fig. 5). Moreover, the *Hro-notch* levels are controlled by dynamic activation of one or more of the MAPK (p38MAPK and ERK) signaling pathways. Initially, the *Hro-notch* level in each cell reflects primarily inherited maternal transcripts. Later, the production and turnover of zygotic transcripts becomes important. The 3' UTR of *Hro-notch* mRNA confers a relatively short half-life to the transcripts, apparently because of the presence of multiple AREs. This instability is



Fig. 4. Exogenous Hro-notch 3' UTR induces degradation of endogenous Hro-notch mRNA. (A-D) Zygotes were injected either with water (A and B) or with 1.1×10^{-6} M Hro-notch 3' UTR (C and D) and then fixed and stained for endogenous Hro-notch (by using a probe specific for the coding region) during the AB phase (310 min AZD; A and C) or CD-2 phase (350 min AZD; B and D). (A and B) Embryos injected with water show the normal AB (13 of 18 embryos) and CD-2 (16 of 24 embryos) phase patterns of Hro-notch; similar results were obtained for embryos injected with a control 3' UTR (from Hro-hes). (C and D) Embryos injected with Hro-notch 3' UTR showed greatly reduced staining in AB (14 of 21 embryos) and CD-2 phases (16 of 18 embryos), suggesting a more rapid turnover and/or reduced transcription of Hro-notch in the presence of exogenous Hro-notch 3' UTR. Top and Bottom in C and D show variability in reduction in staining intensity. All embryos were treated for in situ hybridization in parallel, and in situ coloration reaction was carried out for 10 min. (E) Schematics of Notch 3' UTRs from different species showing varying numbers of AREs (green boxes). Hro-notch 3' UTR bears seven pentameric elements (green). Two of these (underlined blue) overlap and, along with adjacent nucleotides, form two overlapping nonameric AREs (orange line), characteristic of class 2 AREs. GenBank accession numbers for the sequences are indicated. (Scale bar: 100 μ m.)

counteracted by the p38MAPK pathway. Thus, the *Hro-notch* transcript levels are controlled by MAPK signaling at the level of transcript stability and possibly also at the level of transcription. This link between the p38MAPK and Notch pathways persists into later development, because we have observed coincident p38MAPK activation and *Hro-notch* mRNA accumulation in the ectodermal precursor cell DNOPQ (SI Fig. 8).

Another instance where p38MAPK plays a role in early development is in the axial patterning of the *Drosophila* oocyte, where it regulates the availability of the EGF ligand (encoded by *gurken*) and thus controls the activation of the ERK pathway in the follicle cells (27). Although the mechanistic intricacies of combinatorial effects between p38MAPK and other signaling pathways remain to be elucidated, our observations suggest that these effects might involve the regulation of mRNA stability. It has already been demonstrated that oscillations in Notch signaling can be achieved by modulating transcript levels for the



Fig. 5. Summary diagram. (A) Depiction of overall and cell-specific *Hronotch mRNA* and MAPK activation levels during the one- to two-cell stage in *Helobdella*. (B) Model showing synergistic effects of MAPK signaling on transcript stability and predicted zygotic transcription of *Hro-notch*. At first cleavage, maternal *Hro-notch* is distributed uniformly to cells AB and CD and decays under the influence of 3' UTR-dependent degradation, presumably mediated by AREs. In the CD-1 phase, activation of MAPK in CD stabilizes *Hro-notch* mRNA by inhibiting the 3' UTR-dependent degradation. In the AB phase, a switch of MAPK activation from CD to AB is associated with the activation of zygotic transcription and transcript stabilization in that cell, accompanied by destabilization of *Hro-notch* mRNA in CD. Another switch in MAPK activation, from AB to CD, results in the CD-2 phase of *Hro-notch* accumulation. The mechanisms controlling the dynamic MAPK activation remain to be determined.

presumptive ligand (deltaC, in fish presomitic mesoderm) and for a receptor glycosylating enzyme (lunatic fringe, in chick PSM) (28, 29). Our results reveal yet a third mechanism by which oscillatory modulation of Notch signaling may be achieved, namely regulating transcript levels for Notch receptor itself in the two-cell leech embryo. Does this mechanism of Notch regulation operate in other organisms as well? This question can only be answered empirically, but we note that Notch-class genes in a variety of organisms bear several pentameric AREs in their 3' UTRs (Fig. 4E). In particular, the 3' UTR of human Notch-1, like that of Hro-notch, bears nonameric AREs, which makes it a strong candidate for regulation by p38MAPK. The occurrence of AREs within the 3' UTRs of other Notch genes could be a mere coincidence, and the regulation of Notch transcript stability by p38MAPK could be a novelty restricted to leech. This would be a noteworthy result in and of itself, given the frequency with which genes and signaling pathways discovered in one organism prove to have broadly distributed homologs. A more likely alternative, in our opinion, is that our observations provide a relatively prominent, experimentally accessible example of a regulatory interaction that operates throughout the animal kingdom.

Materials and Methods

In Situ Hybridization. Freshly laid zygotes (*Helobdella* sp. collected from Austin, TX) cultured in Htr medium and timed starting from the appearance of the first cleavage furrow were synchronized by grouping embryos that finished first cleavage within 5 min of each other. All *in situ* hybridizations were carried out

under identical conditions of probe concentration $(2 \text{ ng}/\mu \text{l})$, time and temperature of hybridization, and coloration reactions. Details of the *in situ* hybridization and protocol used are the same as described in ref. 9.

sqRT-PCR. Freshly laid zygotes were synchronized as described above. Batches of five embryos for each time window were collected in 25 μ l of Lysis buffer (cells-to-cDNA kit; Ambion, Austin, TX) on ice. Subsequent steps were as recommended by manufacturer. Nineteen microliters of the lysate from each of the reactions was used to set up the RT reaction with 100 units of SuperScript II RT (Invitrogen, Carlsbad, CA). The resulting cDNA was purified through a Qiaquick PCR purification column (Qiagen, Valencia, CA) and eluted in 30 μ l of distilled water. PCR was set up in the presence of 1 unit of AmpliTaq DNA polymerase (Applied Biosystems, Foster City, CA) and 1.5 mM MgCl₂. A 153-bp fragment was amplified by using the following primer pair: NRTF1, AACAAACCCTTCCTACCTGGC and NRTR1, ATCCAGATCGGTCGAACCTGT.

Cycling parameters for the amplification were 95°C for 20 sec, 58°C for 30 sec, and 72°C for 30 sec for an optimal number of cycles (23–32 cycles). To control for RNA extraction variability between individual samples, an \approx 450-bp fragment of 18S cDNA was amplified in parallel by using 18S Classic primer pair (Ambion). Conditions for amplifying the 18S fragment were 95°C for 1 min, 60°C for 1 min, and 72°C for 30 sec for five cycles, followed by 95°C for 1 min, 58°C for 1 min, and 72°C for 30 s.

Amplicons were resolved by electrophoresis on a 1.5% agarose gel containing Etbr. Densitometry analysis was carried out on bands by using Alphaimager (Alpha Innotech, San Leandro, CA). After normalizing for background, ratios of band intensity for *Hro-notch* to that of 18S from different samples were plotted against time.

For sqRT-PCR on embryos treated with actinomycin-D or U0126, embryos were cultured in Htr media containing 500 μ g/ml actinomycin-D (catalog no. A5156l; Sigma–Aldrich, St. Louis, MO) or 50 μ M U0126 (catalog no. V1121; Promega, Madison, WI) and 0.1% DMSO. Actinomycin-D and U0126 were suspended in water or DMSO to obtain stock concentrations of 20 mg/ml and 50 mM, respectively.

Immunostaining. Zygotes were synchronized as described above; details of subsequent steps were as described in ref. 10. Embryos

- 1. Grego-Bessa J, Diez J, Timmerman L, de la Pompa JL (2004) Cell Cycle 3:718-721.
- 2. Kimble J, Simpson P (1997) Annu Rev Cell Dev Biol 13:333-361.
- 3. Evans TC, Crittenden SL, Kodoyianni V, Kimble J (1994) Cell 77:183-194.
- Moloney DJ, Panin VM, Johnston SH, Chen J, Shao L, Wilson R, Wang Y, Stanley P, Irvine KD, Haltiwanger RS, Vogt TF (2000) *Nature* 406:369–375.
 Lai EC (2002) *Curr Biol* 12:R74–R78.
- Frevel MA, Bakheet T, Silva AM, Hissong JG, Khabar KS, Williams BR (2003) Mol Cell Biol 23:425–436.
- Carmena A, Buff E, Halfon MS, Gisselbrecht S, Jimenez F, Baylies MK, Michelson AM (2002) Dev Biol 244:226–242.
- 8. Shaye DD, Greenwald I (2002) Nature 420:686-690.
- 9. Rivera AS, Gonsalves FC, Song MH, Norris BJ, Weisblat DA (2005) *Evol Dev* 7:588–599.
- 10. Huang FZ, Bely AE, Weisblat DA (2001) Curr Biol 11:1-7.
- 11. Guhaniyogi J, Brewer G (2001) Gene 265:11-23.
- Zhang W, Wagner BJ, Ehrenman K, Schaefer AW, DeMaria CT, Crater D, DeHaven K, Long L, Brewer G (1993) *Mol Cell Biol* 13:7652–7665.
- 13. Dean JL, Sully G, Clark AR, Saklatvala J (2004) Cell Signal 16:1113-1121.
- Mahtani KR, Brook M, Dean JL, Sully G, Saklatvala J, Clark AR (2001) Mol Cell Biol 21:6461–6469.
- Rousseau S, Morrice N, Peggie M, Campbell DG, Gaestel M, Cohen P (2002) EMBO J 21:6505–6514.

were incubated in anti-dpp38MAPK (catalog no. M8177l; Sigma–Aldrich, St. Louis, MO) in 1× PBS with 1% Tween 20 and 10% normal goat serum (PTN) at 4°C. Subsequently, embryos were rinsed in 1× PBS containing 1% Tween 20 (PBTw) and incubated in peroxidase-conjugated goat anti-mouse (catalog no. 115–036-003, 1:1,000; Jackson ImmunoResearch, West Grove, PA) in PTN at 4°C overnight. Embryos were then washed in PBTw at room temperature with frequent changes of the wash buffer. Color reaction was carried out in the presence of 0.5 mg/ml diaminobenzidine in $0.75 \times$ PBS and 0.003% H₂O₂. After color development, embryos were dehydrated through an ethanol series and mounted in Murray's-Clear for bright field microscopy (E800; Nikon, East Rutherford, NJ).

Histology. Embryos immunostained for p38MAPKpp were dehydrated through an ethanol series and embedded in glycol methacrylate resin (JB4 embedding kit; Polysciences) as per the manufacturer's instructions. Embryos were sectioned by using a glass knife on a microtome (MT-2B; Sorvall, Newtown, CT). Sections were stained with DAPI (1:1,000 dilution in water) in the dark for 30 min, rinsed with water, air dried, and mounted in Fluormount (BDH) for fluorescence and bright-field microscopy (Nikon).

Plasmid Constructs and in Vitro Transcription. *Hro-notch* 3' UTR was cloned into XbaI/PstI linearized pCS2-egfp plasmid. *egfp-pae* and *egfp::N3'* UTR-*pae* mRNA was transcribed from linearized plasmids by using the mMessage-machine kit as per the manufacturer's instructions (Ambion). mRNA was injected at the indicated concentrations, and embryos were subsequently processed for *in situ* hybridization. Synthetic *Hro-notch* 3' UTR was prepared from linearized pGEMT-Easy bearing Hro-notch-3' UTR by using the T7-megascript kit as per the manufacturer's instructions (Ambion). Purified mRNA was injected into zygotes that were subsequently processed for *in situ* hybridization for *Hro-notch*.

We thank Alexa Bely, John Gerhart, Iswar Hariharan, Françoise Huang, Chris Lowe, Ellen Robey, and members of the Weisblat laboratory for helpful discussions. This work was supported by National Science Foundation Integrative Biology and Neuroscience Grant 0314718 (to D.A.W.).

- 16. Dean JL, Sarsfield SJ, Tsounakou E, Saklatvala J (2003) J Biol Chem 278:39470–39476.
- 17. DeMaria CT, Brewer G (1996) J Biol Chem 271:12179-12184.
- Levy NS, Chung S, Furneaux H, Levy AP (1998) J Biol Chem 273:6417– 6423.
- 19. Chen CY, Chen TM, Shyu AB (1994) Mol Cell Biol 14:416-426.
- 20. Barreau C, Paillard L, Osborne HB (2005) Nucleic Acids Res 33:7138-7150.
- 21. Chen CY, Shyu AB (1995) Trends Biochem Sci 20:465-470.
- Lasa M, Mahtani KR, Finch A, Brewer G, Saklatvala J, Clark AR (2000) Mol Cell Biol 20:4265–4274.
- Yoshida H, Kwon E, Hirose F, Otsuki K, Yamada M, Yamaguchi M (2004) Genes Cells 9:935–944.
- 24. Davies SP, Reddy H, Caivano M, Cohen P (2000) Biochem J 351:95-105.
- 25. Shyu AB, Belasco JG, Greenberg ME (1991) Genes Dev 5:221-231.
- 26. Wilusz CJ, Wormington M, Peltz SW (2001) Nat Rev Mol Cell Biol 2:237-246.
- Suzanne M, Irie K, Glise B, Agnes F, Mori E, Matsumoto K, Noselli S (1999) Genes Dev 13:1464–1474.
- Holley SA, Julich D, Rauch GJ, Geisler R, Nusslein-Volhard C (2002) Development (Cambridge, UK) 129:1175–1183.
- 29. Sato Y, Yasuda K, Takahashi Y (2002) Development (Cambridge, UK) 129:3633-3644.